INmune Bio, Inc. (NASDAQ:INMB) Receives Consensus Rating of “Hold” from Analysts

INmune Bio, Inc. (NASDAQ:INMB) has received a consensus rating of “Hold” from the six research firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $8.00.

A number of equities analysts recently commented on INMB shares. Lucid Cap Mkts raised INmune Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of INmune Bio in a research note on Thursday. Finally, Wall Street Zen lowered INmune Bio from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th.

Hedge Funds Weigh In On INmune Bio

Several institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers lifted its stake in INmune Bio by 14.4% in the first quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock valued at $150,000 after buying an additional 2,409 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in INmune Bio by 20.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock valued at $78,000 after buying an additional 8,427 shares during the period. Royal Bank of Canada lifted its stake in INmune Bio by 44.8% in the first quarter. Royal Bank of Canada now owns 29,863 shares of the company’s stock valued at $233,000 after buying an additional 9,236 shares during the period. Wells Fargo & Company MN lifted its stake in INmune Bio by 79.0% in the fourth quarter. Wells Fargo & Company MN now owns 24,857 shares of the company’s stock valued at $39,000 after buying an additional 10,970 shares during the period. Finally, Intech Investment Management LLC acquired a new position in INmune Bio in the second quarter valued at approximately $26,000. 12.72% of the stock is owned by institutional investors and hedge funds.

INmune Bio Price Performance

INmune Bio stock opened at $1.28 on Tuesday. The stock’s 50 day moving average is $1.37 and its 200 day moving average is $1.48. The firm has a market cap of $34.02 million, a P/E ratio of -0.77 and a beta of 1.03. INmune Bio has a one year low of $1.09 and a one year high of $11.64.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.